AstraZeneca has announced a newly-expanded manufacturing facility in Coppell, Texas, which will double the production of Lokelma for the benefit of patients in the U.S. and around the world. The $445 million investment to expand the facility is part of AstraZeneca’s $50 billion investment in U.S. R&D and manufacturing over the next five years. Jim Fox, Senior Vice President, Americas Supply Operations, AstraZeneca, said: “Our manufacturing facility in Coppell serves as both a critical ...